Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07671534 · ClinicalTrials.gov registry record · Phase 2
Metronomic Gemcitabine, Mitomycin C, and Thalidomide for Advanced Solid Tumors
A Phase 2 study, sponsored by Sarcoma Oncology Research Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT07671534: Recruiting Phase 2 study, sponsored by Sarcoma Oncology Research Center.
NCT07671534 is a Phase 2 study that is actively recruiting participants, run by Sarcoma Oncology Research Center. The registered enrollment target is 60 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07671534, a Phase 2 study, is actively recruiting participants, sponsored by Sarcoma Oncology Research Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
This is an open label phase II study using metronomic low-dose gemcitabine and mitomycin c given intravenously, and thalidomide administered orally, for patients with advanced solid tumors.
Primary Outcome
Progression free survival up to disease progression or death from any cause
Interventions
- DRUG Gemcitabine
- DRUG Mitomycin C
- DRUG Thalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2026-06 |
| Est. Completion | 2029-06 |
| Phase | Phase 2 |
What NCT07671534 shows while recruiting
NCT07671534 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower).
The record links to 0 conditions, and to 3 interventions - of which Gemcitabine is the first listed.
NCT07671534 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07671534 about?
NCT07671534 is a clinical study titled "Metronomic Gemcitabine, Mitomycin C, and Thalidomide for Advanced Solid Tumors". This is an open label phase II study using metronomic low-dose gemcitabine and mitomycin c given intravenously, and thalidomide administered orally, for patients with advanced solid tumors.
What is the current status of trial NCT07671534?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2026-06. Estimated completion is 2029-06.
What interventions are being tested in trial NCT07671534?
The interventions under investigation include: Gemcitabine (DRUG), Mitomycin C (DRUG), Thalidomide (DRUG).
Who is sponsoring clinical trial NCT07671534?
This trial is sponsored by Sarcoma Oncology Research Center, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07671534's enrollment target sits among peer trials
60 1027th of 2000 higher than 868 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia